The scope of nanoparticle therapies for future metastatic melanoma treatment

The Lancet Oncology

Volumn 15, Issue 1, 2014, Pages

  Bombelli, Francesca Baldelli ^a,b   Webster, Carl A ^a   Moncrieff, Marc ^c   Sherwood, Victoria ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b POLITECNICO DI MILANO   (Italy)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARBOXYMETHYLCELLULOSE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DOXORUBICIN; IPILIMUMAB; NANOPARTICLE; PACLITAXEL; VEMURAFENIB;

CANCER CELL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; DRUG RELEASE; GENE MUTATION; HUMAN; IMMUNE SYSTEM; METASTATIC MELANOMA; MOLECULAR MECHANICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 84891369164     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70333-4     Document Type: Review

References (78)

1. Lens MB, Dawes M Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004, 150:179-185.
2. Rigel DS, Russak J, Friedman R The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010, 60:301-316.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
6. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
7. Mura S, Couvreur P Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 2012, 64:1394-1416.
8. Finn L, Markovic SN, Joseph RW Therapy for metastatic melanoma: the past, present, and future. BMC Med 2012, 10:23.
9. Shada AL, Molhoek KR, Slingluff CL Interface of signal transduction inhibition and immunotherapy in melanoma. Cancer J 2010, 16:360-366.
10. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H Melanoma: new insights and new therapies. J Invest Dermatol 2012, 132(3 pt 2):854-863.
11. Gottesman MM Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
12. Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:1836-1843.
13. Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res 2010, 21:44-56.
14. Schicher N, Paulitschke V, Swoboda A, et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 2009, 15:3495-3502.
15. White RM, Cech J, Ratanasirintrawoot S, et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 2011, 471:518-522.
16. Stecca B, Mas C, Clement V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA 2007, 104:5895-5900.
17. Sharma P, Singh A, Brown SC, et al. Multimodal nanoparticulate bioimaging contrast agents. Methods Mol Biol 2010, 624:67-81.
18. Nappini S, Bombelli FB, Bonini M, Norden B, Baglioni P Magnetoliposomes for controlled drug release in the presence of low-frequency magnetic field. Soft Matter 2010, 6:154-162.
19. Choi KY, Liu G, Lee S, Chen XY Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 2012, 4:330-342.
20. Shapira A, Livney YD, Broxterman HJ, Assaraf YG Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Update 2011, 14:150-163.
21. Hu CMJ, Zhang LF Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012, 83:1104-1111.
22. Arora HC, Jensen MP, Yuan Y, et al. Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res 2012, 72:769-778.
23. Ding B, Wu X, Fan W, et al. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int J Nanomedicine 2011, 6:1991-2005.
24. Shelley WB, Talanin N, Shelley ED Polysorbate 80 hypersensitivity. Lancet 1995, 345:1312-1313.
25. Miele E, Spinelli GP, Tomao F, Tomao S Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009, 4:99-105.
26. Kottschade LA, Suman VJ, Amatruda T, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). Cancer 2011, 117:1704-1710.
27. Ernsting MJ, Tang WL, MacCallum N, Li SD Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells. Bioconjug Chem 2011, 22:2474-2486.
28. Ernsting MJ, Murakami M, Undzys E, Aman A, Press B, Li SD A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. J Control Release 2012, 162:575-581.
29. Chaudhuri P, Paraskar A, Soni S, Mashelkar RA, Sengupta S Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano 2009, 3:2505-2514.
30. Zheng D, Li X, Xu H, Lu X, Hu Y, Fan W Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. Acta Biochim Biophys Sin (Shanghai) 2009, 41:578-587.
31. Parhi P, Mohanty C, Sahoo SK Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today 2012, 17:1044-1052.
32. Dilnawaz F, Singh A, Mohanty C, Sahoo SK Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010, 31:3694-3706.
33. Liu XQ, Song WJ, Sun TM, Zhang PZ, Wang J Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol Pharm 2011, 8:250-259.
34. Torchilin VP Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008, 60:548-558.
35. Lentacker I, Geers B, Demeester J, De Smedt SC, Sanders NN Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved. Mol Ther 2010, 18:101-108.
36. Lentacker I, Wang N, Vandenbroucke RE, Demeester J, De Smedt SC, Sanders NN Ultrasound exposure of lipoplex loaded microbubbles facilitates direct cytoplasmic entry of the lipoplexes. Mol Pharm 2009, 6:457-467.
37. Soman N, Marsh J, Lanza G, Wickline S New mechanisms for non-porative ultrasound stimulation of cargo delivery to cell cytosol with targeted perfluorocarbon nanoparticles. Nanotechnology 2008, 19:185102.
38. Harada Y, Ogawa K, Irie Y, et al. Ultrasound activation of TiO2 in melanoma tumors. J Control Release 2011, 149:190-195.
39. Sawant RR, Sriraman SK, Navarro G, Biswas S, Dalvi RA, Torchilin VP Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery. Biomaterials 2012, 33:3942-3951.
40. Perche F, Benvegnu T, Berchel M, et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 2011, 7:445-453.
41. Yang T, Wang Y, Li Z, et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine 2012, 8:81-92.
42. Chen Y, Bathula SR, Yang Q, Huang L Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol 2010, 130:2790-2798.
43. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
44. Bartlett DW, Davis ME Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng 2008, 99:975-985.
45. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hemat 2002, 43:33-56.
46. Lu W, Xiong C, Zhang G, et al. Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clin Cancer Res 2009, 15:876-886.
47. Balivada S, Rachakatla RS, Wang HW, et al. A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer 2010, 10:119.
48. Rachakatla RS, Balivada S, Seo GM, et al. Attenuation of mouse melanoma by a/c magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano 2010, 4:7093-7104.
49. Ishii-Osai Y, Yamashita T, Tamura Y, et al. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model. J Dermatol Sci 2012, 67:51-60.
50. Kim C, Cho EC, Chen J, et al. In vivo molecular photoacoustic tomography of melanomas targeted by bioconjugated gold nanocages. ACS Nano 2010, 4:4559-4564.
51. Benezra M, Penate-Medina O, Zanzonico PB, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest 2011, 121:2768-2780.
52. Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010, 17:3324-3329.
53. Lim SW, Kim HW, Jun HY, et al. TCL-SPION-enhanced MRI for the detection of lymph node metastasis in murine experimental model. Acad Radiol 2011, 18:504-511.
54. Bradbury MS, Phillips E, Montero PH, et al. Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. Integr Biol 2012, 5:74-86.
55. Vannucci L, Falvo E, Fornara M, et al. Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles. Int J Nanomedicine 2012, 7:1489-1509.
56. Maeda H Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 2012, 164:138-144.
57. Okuda T, Kawakami S, Higuchi Y, et al. Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles. Int J Pharm 2009, 373:100-106.
58. Seynhaeve AL, Hoving S, Schipper D, et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007, 67:9455-9462.
59. Cameron MD, Schmidt EE, Kerkvliet N, et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 2000, 60:2541-2546.
60. Paschke R, Heine M, Braun S, Usadel KH Mechanisms of hepatotoxicity caused by dacarbazine in rats. J Cancer Res Clin Oncol 1993, 119:475-481.
61. Choi KY, Jeon EJ, Yoon HY, et al. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials 2012, 33:6186-6193.
62. Jin YJ, Termsarasab U, Ko SH, et al. Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma. Pharm Res 2012, 29:3443-3454.
63. Leenders W, Kusters B, Pikkemaat J, et al. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI. Int J Cancer 2003, 105:437-443.
64. Speiser D, Schwarz K, Baumgaertner P, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 2010, 33:848-858.
65. Goldinger S, Dummer R, Baumgaertner P, et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector Cd8+ T-cell responses in melanoma patients. Eur J Immunol 2012, 42:3049-3061.
66. Raz A, Bucana C, Fogler WE, Poste G, Fidler IJ Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res 1981, 41:487-494.
67. Tassa C, Shaw SY, Weissleder R Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res 2011, 44:842-852.
68. Finkelstein MC, Kuhn SH, Schieren H, Weissmann G, Hoffstein S Liposome uptake by human leukocytes. Enhancement of entry mediated by human serum and aggregated immunoglobulins. Biochim Biophys Acta 1981, 673:286-302.
69. Hrkach J, Von Hoff D, Ali MM, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128ra39.
70. Desai N Challenges in development of nanoparticle-based therapeutics. AAPS J 2012, 14:282-295.
71. Prabhakar U, Blakey DC, Maeda H, et al. Challenges and key considerations of the enhanced permeability and retention effect (EPR) for nanomedicine drug delivery in oncology. Cancer Res 2013, 73:2412-2417.
72. Maeda H Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci 2012, 88:53-71.
73. Alberici L, Roth L, Sugahara KN, et al. De novo design of a tumor-penetrating peptide. Cancer Res 2013, 73:804-812.
74. Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012, 12:39-50.
75. Karmali PP, Simberg D Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv 2011, 8:343-357.
76. Alexis F, Pridgen E, Molnar LK, Farokhzad OC Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
77. Gissi R, Decuzzi P The effect of shape and size in micro-/nanodimples adhesion. J Appl Physiol 2005, 98:014310.
78. Petros RA, Desimone JM Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.